# Medivation: masked candidate comparison

Completed on 12 October 2026. Labels A, B, and C remain masked.

## Result

**A and B tie for first. C ranks third.** All three retain the four reported prices and the principal deal facts.

C omits a required cohort closure at the first due date. Its final financing coding also conflicts with the evidence it elects to use.

The two-round choice in C is not a confirmed error. Nor is its later Pfizer first-contact date.

| Candidate | Major findings | Moderate findings | Minor findings | Substantive rank |
| --- | ---: | ---: | ---: | --- |
| A | 0 | 0 | 0 | Joint first |
| B | 0 | 0 | 0 | Joint first |
| C | 1 | 1 | 1 | Third |

These counts describe confirmed findings in this review. They do not claim that every possible interpretation or workbook property is resolved.

The ranking excludes engine identity, elapsed time, token use, cost, and checker output. No operational receipt was read.

## Evidence and method

The source inventory was complete before candidate access. I did not change that inventory during this review.

I read all four sheets in each masked JSON dump. Each dump supplies the original cell values and Excel row numbers.

I compared the material events and fields with the supplied filing and current instruction. I did not restrict the review to differences between candidates.

I used no other filing, prior workbook, history, engine metadata, or external source. The earlier inventory discloses an incidental regulatory read.

I did not use that extra read to create a finding. C's regulatory question is assessed as a candidate interpretation, not new evidence.

All row references below are **Excel row numbers**, not ledger event numbers. The `#` field appears only where needed for a candidate's own reference.

The source is `_dev/cockpit/state/filings/medivation/medivation_2016-08-30_SCTO-T.htm`. `L` denotes its original HTML line number.

## Confirmed findings

### C1 — Major: the unnamed cohort skips the first required closure

**Affected cells and rows:** C, Deal ledger rows 10, 16, and 22; Rounds rows 2–3; Questions row 2, Q1.

C records the unnamed NDA signers by 5 July. It keeps them continuously live through the 8 August due date.

C then treats the anonymous 10 August invitees as that same cohort. It closes the cohort only on 19 August.

**Source evidence:**

- p. 22, L1467–1468: “entered into confidentiality agreements with several parties, including Sanofi”.
- p. 23, L1484–1486: Pfizer's preliminary proposal is due on 8 August.
- p. 23, L1492–1494: the source reports Pfizer's 8 August offer, but no anonymous cohort offer.
- p. 23, L1495–1496: the target invites Pfizer and “several other interested parties” on 10 August.

**Rule:** E14, closing event 4, closes unnamed members of a reported entrant total with no reported offer at the first due date.

The continuation exception expressly covers events 1 and 3. It does not cover event 4. E3 preserves qualified totals through a blank Count.

C's Q1 acknowledges that limit: “E14’s exception names events 1 and 3 only.” It still recommends uninterrupted participation.

**Why this is confirmed:** The identity link between the two anonymous cohorts is uncertain. That uncertainty does not authorize an exception to E14(4).

Even if both cohorts contain the same parties, the chosen identity interpretation does not remove the required 8 August closure.

C's own alternative states the consequence: an 8 August **Did not submit** event, followed by **Re-entered** before the later admission.

**Research consequence:** C changes the cohort's continuous participation period and suppresses a required exit observation. It keeps unreported participants live through the first deadline.

**Correction principle:** Apply the first-date closure. Then record the later anonymous admission with honest identity uncertainty, or a justified re-entry under the chosen mapping.

Do not create an exact count. Do not treat the source as proof that the two cohort memberships are equal.

**Not separately counted:** The unsupported certainty of the cohort identity and the later closure date arise from the same continuity choice.

### C2 — Moderate: the selected final financing evidence does not support Committed

**Affected cells and rows:** C, Deal ledger row 24, Financing, Conditions, and Note.

C codes the $81.50 bid as **Financing = Committed** and **Conditions = None**.

Its Note states: “Signed agreement has no financing condition; Pfizer funds include cash on hand, no financing commitment.”

**Source evidence:**

- p. 2, L451–455: the final transaction has no financing condition; available funds include cash on hand; no financing commitment was entered.
- p. 21, L1429–1431: available sources include cash on hand, and Pfizer entered no financing commitment for the agreement.
- p. 24, L1519–1521: the $81.50 proposal precedes the agreement on 20 August.

**Rule:** E12 gives an express absence of a firm or committed financing arrangement precedence over a statement that no financing condition applies.

Part B separately limits evidence to the state at the bid's communication. It prevents indiscriminate use of a later disclosure.

**Why this is confirmed:** C elects to use the final financing disclosure for this bid. It cannot use only the favorable half of that disclosure.

If that passage supplies the bid's financing state, E12's priority rule must address the express absence of a commitment.

If the passage falls outside the bid's evidence window, **Not stated** is defensible. It does not support **Committed** through selective use.

An available-internal-funds interpretation could instead support **Not needed**. C does not choose that value or explain why the absence rule does not apply.

**Research consequence:** The row overstates the selected evidence as a commitment. Under the direct E12 priority reading, the financing summary changes to **Heavy/H1**.

**Correction principle:** Choose the temporal interpretation first. Apply the financing rules consistently to all evidence admitted under that interpretation.

**Limit:** This finding does not establish that the final bid necessarily required external finance or faced actual financing risk.

It concerns the instruction's coding and the internal consistency of C's row. A and B's temporal exclusion is addressed separately below.

### C3 — Minor: three Question entries exceed the stated length limit

**Affected rows:** C, Questions rows 2–4, Q1–Q3.

**Rule:** D4 limits each entry to 60 words.

The text across the populated substantive cells totals 103, 95, and 72 words, respectively. These totals exclude the ID and empty reviewer cell.

**Consequence:** The entries exceed the review format. Their meaning remains available, so this does not change the economic assessment.

**Correction principle:** Shorten each entry while retaining the recommendation, source pages, affected rows, and consequence of the alternative.

This is one presentation cause across three entries. It is not three independent findings.

## Ambiguous or defensible choices — not scored as errors

### First contact: 20 April versus 2 May

- A, Deal ledger row 3: 20 April, with the later express transaction interest in the Note.
- B, Deal ledger row 3: the same date choice, with an explicit supporting Review item.
- C, Deal ledger row 4: 2 May, with the earlier attempted contact in the Note.

The 20 April passage requests a discussion. The 2 May passage expressly communicates transaction interest. See p. 22, L1453–1457.

Both choices retain the sequence. Neither changes the bidder-led initiation or Pfizer's NDA entry date. No finding is warranted.

### Initial round date and inference flag

All three open round 1 on 28 June. All retain the 29 June NDA and July disclosure of several NDA parties.

Their Review items explain the unreported wider outreach. This is a defensible use of E6's latest pre-NDA target-step rule.

The frozen inventory also identified a 29 June alternative. It suggested an inference flag for the 28 June reading.

On closer application, Part B distinguishes an inferred event from a classification under a fixed convention. E6 supplies an explicit proxy for this date.

Thus, the absent inference flag is not a confirmed error. Nor is the absence of a mandatory **Process:** Question proved under that reading.

This narrows an inventory review concern. It does not alter the frozen source evidence or create a new preferred reference answer.

### Two rounds versus three

- A: Rounds rows 2–4; Deal ledger rows 17, 20, 23–28; Questions row 7, R6.
- B: Rounds rows 2–4; Deal ledger rows 17, 21, 24–29; Questions row 8, Q1.
- C: Rounds rows 2–3; Deal ledger rows 16, 18, 20–26; Questions row 3, Q2.

A and B read “definitive proposal” as insufficient to announce finality. Their 19 August best-and-final request opens round 3.

C reads the 14 August request as a request for a binding final offer. Its later best-and-final request continues round 2.

The source distinguishes the words but does not define “definitive”. See p. 23, L1498–1500 and p. 24, L1514–1519.

E6's first-stage-request rule and final-round continuation rule support C if its word interpretation is accepted. C identifies the alternative explicitly.

I prefer the stricter three-round reading. The two-round choice remains defensible and does not supply a confirmed major finding.

The same ambiguity affects the 19 August deadline outcome and rival closure mechanism. Those dependent effects are not separate penalties.

### The 19 August deadline in C

C, Rounds row 3, uses **Passed without action; Enforced** for its two due dates. Deal ledger row 23 labels the later communication **Deadline set**.

If the later date extends the same request, E9 gives **Extended** priority and requires **Deadline revised**. A new price request could retain separate due dates.

The source reports a later best-and-final request after the $77 proposal. It reports no intervening target selection decision in that passage.

C does not fully explain the distinction between a new request and an extension. I retain this as an unresolved application issue.

It does not decide the ranking. It depends partly on C's defensible final-stage reading and E9's “same request” criterion.

### The $65 bid: Unclear versus Light

- A, Deal ledger row 15: **Unclear**; Questions row 12 explains the literal rule.
- B, Deal ledger row 15: **Unclear**.
- C, Deal ledger row 14: **Light**, from the approximately one-week forecast.

The source expects diligence and an agreement in approximately one week. It does not call diligence confirmatory, limited, or expedited.

See p. 23, L1492–1494; E12 and amended Part B apply.

The literal **Unclear** reading is stronger. The short forecast can support an expedited-diligence interpretation, which the frozen inventory preserved.

C's Note identifies its trigger. I do not count this disclosed interpretation as a confirmed condition error.

All three correctly retain incomplete diligence and the express lack of a financing condition at the $65 bid.

### Final financing: A and B preserve the temporal issue

A, Deal ledger rows 23 and 27, uses **Financing = Not stated** on the later revisions. Questions row 13 explains the evidence window.

B does the same at Deal ledger rows 24 and 28. Questions row 15 identifies the final disclosure as a filing-date statement.

The final fund-source passage says “currently” and was published on 30 August. It does not separately date its state to each earlier price proposal.

That supports the exclusion chosen by A and B under Part B. Their Formal bids can then have **Conditions = None** through silence.

The alternative use of agreement-related evidence remains debatable. I do not impose **Contingent** on A or B merely from that later passage.

C2 concerns C's inconsistent use of evidence it includes. It does not penalize the other candidates for excluding that evidence coherently.

### Separate admission rows

B, Deal ledger row 19, has a distinct Pfizer admission row. A records the same admission in its round-opening row 17.

C likewise records the admission in round-opening row 16. All three name Pfizer in the corresponding Rounds entry.

The event and Pfizer's continued participation remain visible. I found no lost observation that warrants a penalty or an advantage for the extra row.

This comparison follows the protocol's rule against a reward for extra rows alone.

### Sanofi's inferred exit

All three close Sanofi by 10 August as **Dropped by target**, with an inference flag and **Not stated** exit reason.

The source does not identify Sanofi among the later anonymous invitees. E3's later-group rule and E14 support the chosen convention.

None treats the rejected April offer or the consent withdrawal as a separate sale exit. That avoids unsupported exit and re-entry observations.

The actual later identity remains unknown. The inferred exit is a coding convention, not proof that Medivation expressly excluded Sanofi.

## Complete material coverage review

| Source requirement | A: sheet and Excel row | B: sheet and Excel row | C: sheet and Excel row | Assessment |
| --- | --- | --- | --- | --- |
| Sanofi's $52.50 acquisition proposal and receipt date | Deal ledger 2 | Deal ledger 2 | Deal ledger 2 | All retained; letter date preserved. |
| Public Sanofi bid announcement | Deal ledger 4 | Deal ledger 4 | Deal ledger 3 | Correct separate disclosure, no new price observation. |
| Pfizer's initial approach | Deal ledger 3 | Deal ledger 3 | Deal ledger 4 | Defensible date difference; both contacts retained. |
| Target financial advisers | Deal ledger 5–6 | Deal ledger 5–6 | Deal ledger 5–6 | Correct client and first reported sale involvement. |
| One process and initial stage | Deal ledger 7; Deal facts 11 | Deal ledger 7; Deal facts 11 | Deal ledger 7; Deal facts 11 | No invented restart or termination. |
| Pfizer NDA and invitation | Deal ledger 8 | Deal ledger 8 | Deal ledger 8 | Correct 29 June execution and entry. |
| Sanofi and residual NDA cohort | Deal ledger 9–10 | Deal ledger 9–10 | Deal ledger 9–10 | All preserve qualified residual Count. |
| Sale-process disclosure | Deal ledger 11 | Deal ledger 11 | Deal ledger 11 | Correct 5 July disclosure. |
| Target legal advisers | Deal ledger 12, 21 | Deal ledger 12, 22 | Deal ledger 12, 19 | Correct Cooley and Wachtell client roles. |
| 19 July request and 8 August due date | Deal ledger 13–14 | Deal ledger 13–14 | Deal ledger 13, 15 | All present; next-stage decision supports Enforced. |
| $65 cash bid | Deal ledger 15 | Deal ledger 15 | Deal ledger 14 | Price, cash, Informal status, and incomplete diligence retained. Summary interpretation differs. |
| First unnamed cohort closure | Deal ledger 16 | Deal ledger 16 | Omitted; continuity selected in Questions 2 | Confirmed C1. |
| 10 August next-stage admission | Deal ledger 17, 19; Rounds 3 | Deal ledger 17, 19–20; Rounds 3 | Deal ledger 16; Rounds 3 | Stage present in all; cohort continuity differs. |
| Sanofi's inferred stage exit | Deal ledger 18 | Deal ledger 18 | Deal ledger 17 | Consistent E3/E14 interpretation. |
| Expanded access and target draft | Notes to Deal ledger 17 | Note to Deal ledger 19 | Note to Deal ledger 16 | All retain the stage implementation without another round. |
| 14 August price-and-documents request | Deal ledger 20 | Deal ledger 21 | Deal ledger 18 | All retain both dates; none invents an 18 August bid Deadline. |
| Pfizer's 18 August markup | Note to Deal ledger 23 | Notes to Deal ledger 21, 24 | Note to Deal ledger 20 | Correct support for route 1; no unsupported $65 reaffirmation. |
| $77 cash bid | Deal ledger 23 | Deal ledger 24 | Deal ledger 20 | All correct price and Formal status. No copied $65 conditions. |
| 19 August due date | Deal ledger 22; Rounds 3 | Deal ledger 23; Rounds 3 | Deal ledger 21; Rounds 3 | All present. C outcome has an unresolved request/extension issue. |
| Best-and-final request | Deal ledger 24 | Deal ledger 25 | Deal ledger 23 | All present; coherent two- or three-round interpretations. |
| Subsequent unnamed cohort closure | Deal ledger 25 | Deal ledger 26 | Deal ledger 22 | All close the later cohort; C's earlier continuity defect remains C1. |
| $81.50 cash bid | Deal ledger 27 | Deal ledger 28 | Deal ledger 24 | Correct price and Formal status; C2 affects financing coding. |
| Final due date | Deal ledger 26; Rounds 4 | Deal ledger 27; Rounds 4 | Deal ledger 25; Rounds 3 | All present, with Enforced outcome. |
| Agreement, winner, and cash consideration | Deal ledger 28 | Deal ledger 29 | Deal ledger 26 | Correct date, Pfizer unit, Count 1, consideration in Note. |
| Public merger announcement | Deal ledger 29 | Deal ledger 30 | Deal ledger 27 | Correct 22 August, target Who, post round, blank Count. |
| Initiation and auction screen | Deal facts 10, 13 | Deal facts 10, 13 | Deal facts 10, 13 | Correct bidder-led initiation and Met screen; no false exact total. |

## Further field checks

All candidates use Sanofi's source name and leave its Type Unknown. No candidate imports its business description or outside offer terms.

All treat Pfizer and its shell as one bidder unit. None makes Pfizer's advisers into target Adviser rows.

All keep Sanofi's stock share **Not stated**. All three Pfizer prices have Stock % 0, with no invented contingent payment.

All keep the market price of $67.16 outside the bid-price cells. None creates a separate stock offer or partial-scope bid.

All place the $77 proposal in a Formal row through the price-and-documents request. They do not rely only on the word “definitive”.

All preserve **Not stated** diligence for later Formal bids. None converts silence into a positive statement that diligence is complete.

All leave regulatory and exclusivity conditions unstated on the bid rows. The source background supplies no specific contrary condition.

All separate the agreement from its public announcement. None adds a process termination at the agreement or a round for tender expiration.

The populated dates are consistent with the reported sequence. The “by 5 July” NDA rows retain an upper bound without an invented lower bound.

All candidate quotes fit the 30-word limit under ordinary whitespace counts. Their cited background passages support the principal event claims.

I found no missing required core bid field in the dumps. None uses the reviewer-note fields to substitute for a required observation.

The material Questions and Review references correspond to the intended ledger events. C3 concerns entry length, not a missing explanation.

## Why A and B tie

A and B preserve the same material event structure and economic coding. Both apply the required initial cohort closure.

Both state the later cohort identity limit. Both explain their final-stage choice and later bid condition windows.

B provides a separate Pfizer admission row and more cross-page pointers. A contains the same economic information in the opening row and Notes.

Those differences do not support a substantive rank difference. Neither candidate has a confirmed source error from this review.

## Limits and completion

This review covers source accuracy in the supplied cell dumps. It does not verify workbook styling, filters, date formats, file integrity, or actual runtime.

The source omits most rival details. No candidate can recover an exact competitor population or the missing rival prices from this evidence.

The finality, cohort identity, and financing timing issues remain separate from the confirmed violations. Agreement between candidates does not resolve them.

The manager should verify C1 and C2 against the cited source and instruction before any unmasked recommendation.

No candidate file, workbook, or source inventory was changed. No extraction, model call, test, web request, or subagent was used.
